These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 31249945)

  • 1. Effects of Plasmin on von Willebrand Factor and Platelets: A Narrative Review.
    van der Vorm LN; Remijn JA; de Laat B; Huskens D
    TH Open; 2018 Apr; 2(2):e218-e228. PubMed ID: 31249945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
    Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
    Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
    Shin Y; Miyake H; Togashi K; Hiratsuka R; Endou-Ohnishi K; Imamura Y
    J Biochem; 2018 May; 163(5):381-389. PubMed ID: 29228282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
    Brophy TM; Ward SE; McGimsey TR; Schneppenheim S; Drakeford C; O'Sullivan JM; Chion A; Budde U; O'Donnell JS
    Arterioscler Thromb Vasc Biol; 2017 May; 37(5):845-855. PubMed ID: 28279966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura.
    Moore JC; Murphy WG; Kelton JG
    Br J Haematol; 1990 Apr; 74(4):457-64. PubMed ID: 2346725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
    Budde U; Schneppenheim R
    Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving our understanding on the clinical role of plasmin-mediated von Willebrand factor degradation.
    Otmani HE; Vanhoorelbeke K; Tersteeg C
    Curr Opin Hematol; 2024 May; ():. PubMed ID: 38723202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo.
    Hamilton KK; Fretto LJ; Grierson DS; McKee PA
    J Clin Invest; 1985 Jul; 76(1):261-70. PubMed ID: 3160727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic resistance conferred to fibrinogen by von Willebrand factor.
    Tanka-Salamon A; Kolev K; Machovich R; Komorowicz E
    Thromb Haemost; 2010 Feb; 103(2):291-8. PubMed ID: 20024497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Platelet--vessel wall interactions].
    Baruch D
    Therapie; 2006; 61(5):371-8. PubMed ID: 17243265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.
    Tersteeg C; Fijnheer R; Pasterkamp G; de Groot PG; Vanhoorelbeke K; de Maat S; Maas C
    Semin Thromb Hemost; 2016 Feb; 42(1):9-17. PubMed ID: 26595154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation studies in thrombotic thrombocytopenic purpura, with special reference to von Willebrand factor and protein S.
    Takahashi H; Tatewaki W; Nakamura T; Hanano M; Wada K; Shibata A
    Am J Hematol; 1989 Jan; 30(1):14-21. PubMed ID: 2521276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy.
    Byrnes JJ; Moake JL
    Clin Haematol; 1986 May; 15(2):413-42. PubMed ID: 3524932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.
    Arai S; Allan C; Streiff M; Hutchins GM; Vogelsang GB; Tsai HM
    Hematol J; 2001; 2(5):292-9. PubMed ID: 11920264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.
    Tsai HM; Rice L; Sarode R; Chow TW; Moake JL
    Ann Intern Med; 2000 May; 132(10):794-9. PubMed ID: 10819702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Von Willebrand factor and ADAMTS13 balancing primary haemostasis].
    Schneppenheim R; Budde U
    Hamostaseologie; 2011 Nov; 31(4):275-80. PubMed ID: 21792464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biology of von Willebrand factor].
    Girma JP
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S143-8. PubMed ID: 17373215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma.
    Clark CC; Mebius MM; de Maat S; Tielens AGM; de Groot PG; Urbanus RT; Fijnheer R; Hazenberg BPC; van Hellemond JJ; Maas C
    Thromb Haemost; 2018 Mar; 118(3):471-479. PubMed ID: 29534248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the mechanism of plasmin-induced aggregation of human platelets: implication of secreted von Willebrand factor.
    Rabhi-Sabile S; de Romeuf C; Pidard D
    Thromb Haemost; 1998 Jun; 79(6):1191-8. PubMed ID: 9657447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Von Willebrand factor regulates complement on endothelial cells.
    Noone DG; Riedl M; Pluthero FG; Bowman ML; Liszewski MK; Lu L; Quan Y; Balgobin S; Schneppenheim R; Schneppenheim S; Budde U; James P; Atkinson JP; Palaniyar N; Kahr WH; Licht C
    Kidney Int; 2016 Jul; 90(1):123-34. PubMed ID: 27236750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.